Alex Najera, MD
Internal Medicine · Pasco, WANPI 1780790493
Payments from drug & device makers
Across 340 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$960
- AbbVie$675
- Novo Nordisk$377
- Sumitomo Pharma America, Inc.$336
- Bayer$333
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,93997%
- Education$1613%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $1,094 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 61 | $960 |
| AbbVie(2 entities) | 41 | $675 |
| Novo Nordisk | 23 | $377 |
| Sumitomo Pharma America, Inc. | 14 | $336 |
| Bayer | 13 | $333 |
| Pfizer | 20 | $305 |
| Novartis | 14 | $271 |
| Astellas Pharma US Inc | 7 | $224 |
| Lilly USA, LLC | 12 | $192 |
| Merck | 11 | $166 |
| Sanofi-aventis U.S. LLC | 8 | $141 |
| Mylan Specialty L.p. | 7 | $139 |
| Boehringer Ingelheim | 7 | $132 |
| Sunovion Pharmaceuticals Inc. | 5 | $115 |
| Abbott | 4 | $87 |
| Amgen | 5 | $85 |
| Johnson & Johnson | 4 | $83 |
| Exact Sciences | 3 | $63 |
| Eisai Inc. | 3 | $44 |
| Merz North America, Inc. | 1 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| GSK | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Corcept Therapeutics | 1 | $14 |
| Grifols USA, LLC | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
How this compares
$6,099 in reported general payments places this provider in the 95th percentile of 2,038 internal medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 136 | $189,645 |
| JardianceEmpagliflozin | 125 | $174,180 |
| RybelsusSemaglutide | 54 | $80,342 |
| GemtesaVibegron | 68 | $74,131 |
| EliquisApixaban | 78 | $71,066 |
| LinzessLinaclotide | 68 | $54,384 |
| NamzaricMemantine Hcl/Donepezil Hcl | 29 | $46,539 |
| TrulancePlecanatide | 31 | $44,868 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $31,332 |
| MyrbetriqMirabegron | 25 | $23,941 |
| EntrestoSacubitril/Valsartan | 16 | $20,246 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $16,307 |
| XareltoRivaroxaban | 19 | $15,300 |
| JanuviaSitagliptin Phosphate | 15 | $10,415 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $7,914 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,094 | $205,952148 claims |
| Boehringer IngelheimJardiance | $132 | $174,180125 claims |
| AbbVieLinzess, Namzaric, Synthroid | $675 | $102,034122 claims |
| Novo NordiskRybelsus | $377 | $80,34254 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $336 | $74,13168 claims |
| PfizerEliquis | $305 | $71,06678 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $960 | $44,86831 claims |
| GSKTrelegy Ellipta | $20 | $31,33242 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $23,94125 claims |
| NovartisEntresto | $271 | $20,24616 claims |
| Johnson & JohnsonXarelto | $83 | $15,30019 claims |
| MerckJanuvia | $166 | $10,41515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,038 internal medicine providers in Washington.
Other internal medicine in Pasco
- Sabrina BenjaminOlympia$7.9M
- Ryan AhernSeattle$7.3M
- Eric KleinOlympia$2.4M
- Scott RamseySeattle$2M
- Vidya MenonTacoma$1.8M
- Peter ShalitSeattle$1.8M
- Yuan Po TuEverett$1.6M
- Peiqing QianSeattle$1.5M
- Radica AlicicSpokane$1.5M
- Shelly KhuranaLynnwood$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.